Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment

Inclusion Criteria: * Histologically confirmed locally advanced or metastatic colorectal cancer * Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors * ECOG performance status ≤ 2 * Age 18 - 72 years * Patients who progress after 1st line therapy with FOLFOX/AVASTIN * Adequate liver (Bilirubin ≤ 1.5 upper normal limit, SGOT/SGPT ≤ 4 upper normal limit, ALP ≤ 2.5 upper normal limit) renal (Creatinine ≤ 1.5 upper normal limit) and bone marrow (ANC ≥ 1,500/mm3, PLT ≥100,000/mm3) function * Patients must be able to understand the nature of this study * Written informed consent Exclusion Criteria: * History of serious cardiac disease (unstable angina, congestive heart failure,uncontrolled cardiac arrhythmias) * History of myocardial infarction or stroke within 6 months * Clinically significant peripheral vascular disease * History of abdominal fistula, gastrointestinal perforation or intraabdominal abscess within 28 days prior to Day 0 * Major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Day 1 * Presence of central nervous system or brain metastasis * Evidence of bleeding diathesis or coagulopathy * Blood pressure \> 150/100 mmHg * Pregnant or lactating woman * Life expectancy \< 3 months * Previous radiotherapy within the last 4 weeks or \> 25% of bone marrow * Metastatic infiltration of the liver \> 50% * Patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction or total colectomy * Active infection requiring antibiotics on Day 1 * Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer * Psychiatric illness or social situation that would preclude study compliance